NCT05682560CompletedPhase 2
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
Source: ClinicalTrials.gov · Last updated 24 Mar 2025
Brief summary (registry, in English)
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 11 Jan 2023
- Start date
- 4 May 2023
- Primary completion date
- 26 Jul 2024
- Lead sponsor
- StemCyte, Inc.
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05682560
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 30
- From 4 May 2023 to the primary completion date, 26 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1\. Neurological disorders prior to COVID-19 diagnosis
- 5\. Is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening
- 6\. Has received any vaccination within 3 weeks prior to the first IP infusion
Other illness
- 2\. With pre-existing terminal illness
- 3\. With known immune disease
- 8\. Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters
Other
- 4\. Is pregnant or breastfeeding
- 7\. Judged by the investigator to be not suitable for study participation
Who the study is looking for
- 1\. Male or female aged ≥ 18
- 2\. With post-COVID syndrome
- 3\. Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)
- 4\. Able to provide signed informed consent (by the subject or his/her legally authorized representative)
- 5\. Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Myrak Research Center Coordinator of this site? Confirm its status | Miami Lakes | United States | Unknown status |
Related publications
- REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial.EClinicalMedicine · 2026 · PMID 41625963
This page is information, not medical advice. Discuss any trial with your doctor.